Histotripsy for Ablation of Liver Tumours in Asia

The HALT study aims to evaluate histotripsy in an Asian population for both primary (HCC, CCA) and secondary liver malignancies with liver-limited or oligoprogressive disease. In addition to safety and local control, the study incorporates translational endpoints including immune profiling (PBMCs, cytokines), microbiome shifts, and optional tumour biopsies. This trial will provide critical data on the feasibility, tolerability, and biological impact of histotripsy in a region with the highest burden of liver cancer.

Trial Details

NCT ID
NCT07428356
Phase
NA
Sponsor
National Cancer Centre, Singapore
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Histotripsy using HistoSonics Edison™ System
Locations (sample)
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007
  • Singapore, Singapore|1.28967,103.85007

Key Eligibility Criteria

  • Age ≥21 years at the time of consent.
  • Histologically/cytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC):
  • A) Liver limited malignancies (primary or secondary) not eligible for/declined resection or other locoregional treatment modalities.
  • B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver diseas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →